---
title: "Obefazimod (ABX464): Ulcerative colitis"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis. Clinical evidence covers ABTECT-1, ABTECT-2, ABTECT maintenance, ABX464-103, ABX464-104, ABX464-101, and 9 further headings. 908 evidence topics quoted from 173 sources. Every quote links to the document it came from."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464): Ulcerative colitis

<a id="executive-summary"></a>

## 1 Executive Summary

<a id="heading-1.1"></a>

### 1.1 Clinical Benefits of Obefazimod

<a id="heading-1.1.1"></a>

#### 1.1.1 Burden of Ulcerative colitis

<a id="topic-1.1.1-1"></a>

##### Summary: epidemiology and natural history

In a U.S. study, the age-, sex-, and insurance-standardized prevalence of ulcerative colitis was 378 per 100,000 population (95% CI 375 to 382); extrapolated to the 2020 census, the authors estimated 1.253 million Americans with ulcerative colitis. In the same study, the incidence of ulcerative colitis (6.3, 95% CI 6.1 to 6.6) was higher than that of Crohn's disease (4.1, 95% CI 3.9 to 4.3) and peaked in the third decade of life. ICER reports approximately 160,000 people with ulcerative colitis (0.64%) among 25 million Medicare fee-for-service beneficiaries. Worldwide, the prevalence of ulcerative colitis was estimated at 5 million cases in 2023, and “the incidence is increasing worldwide.”

ICER's 2020 report cites the Crohn's and Colitis Foundation for the statement that approximately 22% of patients with ulcerative colitis “have moderate-to-severe disease activity in a given year”, and in a Copenhagen cohort diagnosed in 2003 to 2004, early disease activity was moderate-to-severe in 24%. In a company estimate, Abivax states that approximately 300,000 moderate-to-severe U.S. patients, out of an estimated 500,000, are on conventional therapy or steroids only, and that U.S. advanced therapy use reached approximately 271,000 patients in 2025. Among 3,893 patients with newly diagnosed ulcerative colitis, cumulative 5-year use of advanced therapy was 29% (95% CI 27 to 31), and 38% (95% CI 34 to 41) among patients diagnosed in 2019 to 2023.

The disease course is most often relapsing and remitting. A review reports a cumulative risk of relapse of 70% to 80% at 10 years and an aggressive course in about 10% to 15% of patients. At diagnosis, a median of 40.1% of patients had left-sided colitis, 30.5% extensive colitis, and 29.4% proctitis. In the cohort of 3,893 newly diagnosed patients, the cumulative 5-year risk of IBD-related hospitalization was 11% (95% CI 10 to 12) and of colectomy 5.7% (95% CI 4.8 to 6.7), with a 5-year colectomy risk of 4.2% among patients diagnosed in 2019 to 2023 against 6.7% among those diagnosed in 2007 to 2012. Across 26 studies, 1-, 5-, and 10-year colectomy risks were 4.0%, 8.8%, and 13.3%, and contemporary risks were 2.8%, 7.0%, and 9.6%. A review states that “10-20% of patients still require proctocolectomy for medically refractory disease.”

Sources differ on mortality. The all-cause summary standardized mortality ratio across inception cohort and population cohort studies was 1.19 (95% CI 1.06 to 1.35), with increased mortality from colorectal cancer, pulmonary disease, and nonalcoholic liver disease and decreased mortality from cardiovascular disease, and a review reports life expectancy of approximately 80.5 years for females and 76.7 years for males, “approximately 5 years shorter than people without UC.” Another review states that ulcerative colitis “has not been associated with an increased mortality, as compared to the general population, except in one cohort”.

Source: [Lewis et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10592313/); [ICER special assessment of Entyvio to inform CMS negotiation (2026)](https://icer.org/wp-content/uploads/2026/03/Entyvio_Final-Evidence-Report_For-Publication_030326.pdf); [Le Berre et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37573077/); [ICER Targeted Immune Modulators for Ulcerative Colitis final evidence report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_UC_Final_Evidence_Report_101620.pdf); [Fumery et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6658168/); [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm); [Ahuja et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13456955/); [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463); [Tsai et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8934200/); [Bewtra et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3755276/); [Gros and Kaplan (2023)](https://pubmed.ncbi.nlm.nih.gov/37698559/)

<a id="topic-1.1.1-2"></a>

##### Summary: long-term morbidity and humanistic burden

A review states that the risk of colorectal cancer after 20 years of disease duration is 4.5% and that people with ulcerative colitis have a 1.7-fold higher risk than the general population. In a cohort study, incident colorectal cancer occurred at 1.29 per 1000 person-years in the ulcerative colitis cohort and 0.82 per 1000 person-years in reference individuals (HR 1.66, 95% CI 1.57 to 1.76); during 2013 to 2017 (Sweden only), the HR was 1.38 (95% CI 1.20 to 1.60). Across 52 studies reporting on 352 454 patients, the prevalence of at least one joint, ocular, or skin extraintestinal manifestation was 27% in ulcerative colitis. Among patients with newly diagnosed ulcerative colitis, the cumulative 5-year risk of serious infection was 10.2% (95% CI 9.1 to 11.4). Patients with ulcerative colitis had a 1.8 times higher risk of work disability (95% CI 1.4 to 2.3) than the general population.

Among 289 U.S. and 1037 EU5 participants with moderate-to-severe ulcerative colitis, those with active disease reported lower EQ-5D health state utilities (adjusted means 0.87 in the U.S. and 0.78 in the EU5) than those in remission (0.92 and 0.91). In a survey of 2100 participants across 10 countries, participants reported a mean of 4.3 flares (SD 7.4) in the past year, 84% of patients with moderate to severe disease reported ulcerative colitis to be “mentally exhausting”, 65% felt that ulcerative colitis controlled their life, and 21% and 15% reported a diagnosis of anxiety or depression, respectively. In a survey of 200 U.S. and 556 European participants, 45.0% of U.S. and 37.0% of European patients reported wearing diapers, pads, or protection at least once a week in the past 3 months due to fear or anticipation of fecal urge incontinence, and among patients who had experienced bowel urgency, 78.0% of U.S. and 77.2% of European patients reported that it negatively affected work or school. Across 77 studies including 30 118 patients with inflammatory bowel disease, the pooled prevalence of anxiety symptoms was 32.1% and of depression symptoms 25.2%, and both were higher in active than in inactive disease.

Source: [Gros and Kaplan (2023)](https://pubmed.ncbi.nlm.nih.gov/37698559/); [Olén et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31929014/); [Kilic et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37042969/); [Ahuja et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13456955/); [Fumery et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6658168/); [Armuzzi et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6975026/); [Dubinsky et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8528151/); [Travis et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11144997/); [Barberio et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33721557/)

<a id="topic-1.1.1-3"></a>

##### Summary: economic burden

ICER's 2020 report states that the economic burden of ulcerative colitis in the United States ranges “between an estimated $15-32 billion per year”, and ICER's 2026 report cites recent estimates of $50 billion per year for inflammatory bowel disease. In MarketScan insurance claims data for 85,755 patients with ulcerative colitis, the lifetime incremental cost averaged $230,102 for a diagnosis at any age and the lifetime total cost was $405,496 (2016 U.S. dollars, discounted at 3% per annum). Among 52,782 patients with inflammatory bowel disease (29,062 with ulcerative colitis), direct costs were $22,987 per member per year against $6956 for controls, and mean costs were $26,555 in the first year after diagnosis.

Costs were higher with treatment failure and with chronic corticosteroid use. In one analysis, 75% of patients experienced treatment failure within the first 12 months, and mean all-cause costs were $74 995 in the treatment failure cohort against $56 169 in the persistent cohort. Among 3562 patients initiating advanced therapy, 12.2% had a UC-related hospitalization within 12 months and mean unadjusted UC-related costs were $42,579. Mean all-cause total costs per patient per year were $73,491 for chronic against $58,884 for nonchronic corticosteroid users among targeted treatment initiators, and $39,335 against $21,271 among conventional therapy initiators. The median index hospitalization cost of nonelective colectomy or rectal resection was $40,300 (IQR $26,400 to $65,000) among an estimated 10,280 patients.

Among 282 patients with ulcerative colitis, annual indirect costs due to total work impairment rose from $4348 per patient per year in remission to $24 283 per patient per year in moderately-to-severely active disease. The authors of a U.S. and EU5 survey estimated that the observed work impairment would equate to $15,400 in lost wages per employed patient with ulcerative colitis per year in the United States. In the survey of 2100 participants across 10 countries, 74% of employed patients reported work absence because of ulcerative colitis, missing a mean of 8.1 working days in the past 12 months. Patients with inflammatory bowel disease paid $2213 against $979 in out-of-pocket costs per year compared with patients without it. In a review of 25 studies (12 eligible for meta-analysis), the pooled prevalence of caregiver burden was 470 per 1000 carers, and in a study of 102 participants with inflammatory bowel disease and their caregivers, 39% of caregivers experienced burden.

Source: [ICER Targeted Immune Modulators for Ulcerative Colitis final evidence report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_UC_Final_Evidence_Report_101620.pdf); [ICER special assessment of Entyvio to inform CMS negotiation (2026)](https://icer.org/wp-content/uploads/2026/03/Entyvio_Final-Evidence-Report_For-Publication_030326.pdf); [Lichtenstein et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31326606/); [Park et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7534391/); [Lee et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11094759/); [Long et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7216775/); [Zhdanava et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10839463/); [Ng et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38583900/); [Ding et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9802455/); [Armuzzi et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6975026/); [Dubinsky et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8528151/); [Dadoo et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13312674/); [Zand et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7302133/)

<a id="topic-1.1.1-4"></a>

##### Summary: limitations of current therapies

A review states that “the highest response to these treatments ranges from 30% to 60% in clinical trials.” The ACG 2025 guideline states that up to one-fifth of patients receiving anti-TNF agents may not respond initially and that “an additional 10%–15% may lose response every year”. The ECCO 2026 guideline states that 10% to 13% of patients on anti-TNFs lose response annually and that 40% of patients on vedolizumab maintenance therapy lose response, of whom approximately half recapture response with dose escalation. Among 3562 patients initiating advanced therapy, 83.0% had used steroids in the preceding 12 months and 47.8% remained steroid-free after 12 months. The Xeljanz label carries a boxed warning for serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis. The Velsipity label requires assessments before initiation and lists myocardial infarction, unstable angina pectoris, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or Class III or IV heart failure experienced in the last 6 months. Abivax states that biological agents require injections or intravenous infusions, “resulting in patient inconvenience and burden, which often negatively impacts patient compliance.”

Obefazimod is investigational, and Abivax states that it “has not yet been approved for commercial use in any jurisdiction.” No FDA application has been submitted; Abivax states that it “remains on track to submit its first NDA for obefazimod by the end of 2026.” The results of the ABTECT trials come from company press releases, filings, and congress presentations, and for the two induction trials also from ClinicalTrials.gov results first posted on September 10, 2026; no peer-reviewed full publication of the ABTECT trials exists as of November 2026.

Source: [Gros and Kaplan (2023)](https://pubmed.ncbi.nlm.nih.gov/37698559/); [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463); [Gisbert et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/7/jjag066/8726617); [Long et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7216775/); [Xeljanz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/203214s042lbl.pdf); [Velsipity prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/216956s002lbl.pdf); [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm); [Abivax obefazimod web page](https://www.abivax.com/our-science/obefazimod/); [Abivax press release, pre-NDA interaction with the FDA (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-pre-nda-interaction-fda-obefazimod); [ClinicalTrials.gov NCT05507203](https://clinicaltrials.gov/study/NCT05507203); [ClinicalTrials.gov NCT05507216](https://clinicaltrials.gov/study/NCT05507216)

<a id="heading-1.1.2"></a>

#### 1.1.2 Obefazimod Efficacy and Safety

<a id="topic-1.1.2-1"></a>

##### Summary: regulatory status and evidence base

Obefazimod (ABX464) is an investigational oral small molecule for moderately to severely active ulcerative colitis. It is not approved in any jurisdiction, and no new drug application (NDA) has been submitted to the FDA; after a pre-NDA interaction, Abivax states that it “remains on track to submit its first NDA for obefazimod by the end of 2026”.

The phase 3 evidence comprises two 8-week placebo-controlled induction trials, ABTECT-1 and ABTECT-2, and the 44-week ABTECT Maintenance trial. The ABTECT results come from congress abstracts, posters, and slide presentations, company press releases and filings, and the ClinicalTrials.gov results of the two induction trials, first posted on 2026-09-10. The ClinicalTrials.gov record of the maintenance trial shows “No Results Posted”. No peer-reviewed full publication of any ABTECT trial exists as of the latest source. The phase 2 evidence comprises a phase 2a induction trial (ABX464-101) and its open-label extension (ABX464-102), a phase 2b dose-ranging induction trial (ABX464-103) and its open-label maintenance study (ABX464-104), and the ongoing open-label long-term extension Study 108 (ABX464-108).

Source: [Abivax obefazimod web page](https://www.abivax.com/our-science/obefazimod/); [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf); [Abivax press release, pre-NDA interaction with the FDA (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-pre-nda-interaction-fda-obefazimod); [ClinicalTrials.gov NCT05507203](https://clinicaltrials.gov/study/NCT05507203); [ClinicalTrials.gov NCT05507216](https://clinicaltrials.gov/study/NCT05507216); [ClinicalTrials.gov NCT05535946](https://clinicaltrials.gov/study/NCT05535946); [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/); [Abivax press release, phase 2a induction results (2018)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-impressive-results-clinical-phase-2a-trial-abx464); [ClinicalTrials.gov NCT03760003](https://clinicaltrials.gov/study/NCT03760003); [ClinicalTrials.gov NCT04023396](https://clinicaltrials.gov/study/NCT04023396); [ClinicalTrials.gov NCT05177835](https://clinicaltrials.gov/study/NCT05177835)

<a id="topic-1.1.2-2"></a>

##### Summary: induction efficacy in ABTECT-1 and ABTECT-2

In ABTECT-1, 636 participants were analyzed (318 receiving obefazimod 50 mg, 160 receiving obefazimod 25 mg, and 158 receiving placebo once daily), and in ABTECT-2, 636 participants (318, 159, and 159). The FDA primary endpoint was clinical remission by the modified Mayo Score at Week 8.

- ABTECT-1: clinical remission occurred in 21.7% (69/318) with 50 mg and 23.8% (38/160) with 25 mg against 2.5% (4/158) with placebo; the placebo-adjusted differences were 19.3% and 21.4% (both p<0.0001). Each key secondary endpoint had p<0.0001 at both doses, including endoscopic improvement (33.3% with 50 mg and 37.5% with 25 mg against 5.7%) and clinical response (61.0% and 65.6% against 28.5%).
- ABTECT-2: clinical remission occurred in 19.8% (63/318) with 50 mg against 6.3% (10/159) with placebo, a difference of 13.4% (p=0.0001). The 25 mg dose did not meet the primary endpoint (11.3% [18/159]; difference 5.1%, p=0.1034), so the p-values of its key secondary endpoints are nominal. Endoscopic improvement occurred in 35.5% with 50 mg and 22.0% with 25 mg against 10.1% with placebo.
- For the EMA, endoscopic improvement and symptomatic remission were co-primary endpoints, which were “met by both doses in both trials”.
- In the pooled analysis of both trials, for which all p-values are nominal, clinical remission at Week 8 occurred in 20.8% (132/636) with 50 mg and 17.6% (56/319) with 25 mg against 4.4% (14/317) with placebo (differences 16.4% and 13.2%).
- Pooled patient-reported outcomes (nominal p-values): at Week 8, 37% of participants receiving 50 mg reported no bowel urgency against 18.1% receiving placebo, and a meaningful within-patient change in IBDQ total score occurred in 60.9% (50 mg) and 56.9% (25 mg) against 39.8% (placebo).
- In a post hoc pooled analysis by baseline disease extent, the placebo-adjusted difference in clinical remission with 50 mg was 19.5% in proctosigmoiditis and 23.6% in left-sided colitis (both nominal p<0.0001); in extensive colitis, nominally significant differences with 50 mg were reported for clinical response, symptomatic response and remission, endoscopic improvement, and HEMI. In a pooled analysis by baseline disease duration, the difference in clinical remission with 50 mg was 20.6% with disease duration under 2 years, 17.8% with 2 to 10 years, and 12.5% with 10 years or more.

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/); [ClinicalTrials.gov NCT05507203 results](https://clinicaltrials.gov/study/NCT05507203?tab=results); [ClinicalTrials.gov NCT05507216 results](https://clinicaltrials.gov/study/NCT05507216?tab=results); [Abivax press release, ABTECT induction results (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-phase-3-results-both-abtect-8-week); [Abivax press release, patient-reported outcomes from ABTECT induction (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-patient-reported-outcomes-data-phase-3-abtect); [Baert et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/Supplement_1/jjaf231.098/8432840); [Heeren et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/Supplement_1/jjaf231.097/8432669); [D'Haens et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/Supplement_1/jjaf231.138/8432748); [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="topic-1.1.2-3"></a>

##### Summary: maintenance efficacy in ABTECT Maintenance

- Design: Part 1 re-randomized 580 participants with a clinical response to 8 weeks of obefazimod induction to placebo (192), obefazimod 25 mg (193), or obefazimod 50 mg (195) once daily for 44 weeks. Placebo induction responders were maintained on blinded placebo and are not among the 580.
- Primary endpoint: clinical remission at Week 44 occurred in 50.8% (98/193) with 25 mg and 51.3% (100/195) with 50 mg against 10.4% (20/192) with placebo; the adjusted differences were 39.3 and 40.3 percentage points (both p<0.0001). The UEG Week 2026 presentation reports the same results as Week 52, counting the 8-week induction.
- Secondary endpoints reported by the company, each with p<0.0001 at both doses: endoscopic improvement in 54.9% (25 mg) and 64.1% (50 mg) against 12.5% (placebo); endoscopic remission in 41.5% and 47.7% against 9.9%; HEMI in 50.3% and 57.4% against 10.4%; corticosteroid-free clinical remission in 45.1% and 47.7% against 9.9%; and sustained clinical remission, among participants in clinical remission at Week 8 of induction, in 67.1% (49/73) and 65.6% (40/61) against 15.7% (8/51). The congress presentation states that both doses “met all multiplicity-controlled key secondary endpoints”.
- Completion of Week 44 without relapse or treatment switch was 78.8% (152/193) with 25 mg and 82.1% (160/195) with 50 mg against 34.3% (66/192) with placebo.
- Part 2, which has no placebo group, reported exploratory endpoints at Week 44. Among induction non-responders who continued obefazimod, clinical remission occurred in 23.5% with 25 mg (N=81) and 37.2% with 50 mg (N=148). Among Part 1 relapsers re-treated with 50 mg, it occurred in 45.0% of those previously receiving placebo (N=109) and 45.5% of those previously receiving 25 mg (N=33).

Source: [Abivax press release, ABTECT maintenance results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-landmark-phase-3-abtect-maintenance-trial); [Sands et al. (2026a)](https://www.abivax.com/wp-content/uploads/2026/10/OP097-ABTECT-Topline-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-Obe-1.pdf); [Abivax press release, ABTECT maintenance Part 2 results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-positive-abtect-maintenance-part-2-results); [ClinicalTrials.gov NCT05535946](https://clinicaltrials.gov/study/NCT05535946)

<a id="topic-1.1.2-4"></a>

##### Summary: efficacy by prior inadequate response to advanced therapy

- Induction, pooled analysis (nominal p-values): 602 of 1,272 participants (47.3%) had a prior inadequate response to an advanced therapy (AT-IR). Clinical remission at Week 8 with 50 mg occurred in 13.3% against 3.4% with placebo in AT-IR participants (difference 10.1%, p=0.0009) and in 27.7% against 5.3% in participants without AT-IR (difference 22.4%, p<0.0001). With 25 mg in AT-IR participants, it occurred in 6.8% (difference 3.5%, p=0.1728). Among participants with prior JAK inhibitor failure, clinical response occurred in 54.5% (30/55) with 50 mg and 47.1% (16/34) with 25 mg against 20.0% (7/35) with placebo.
- Maintenance at Week 52 (unadjusted differences and nominal p-values, which the presenters state “should be interpreted as descriptive rather than confirmatory”): among participants with prior AT-IR, clinical remission occurred in 26 of 76 (25 mg) and 38 of 90 (50 mg) against 5 of 72 (placebo), differences of 28% and 33%; among AT-IR-naive participants, in 72 of 117 and 62 of 105 against 15 of 120, differences of 48% and 45%. Among participants with prior JAK inhibitor inadequate response, clinical remission occurred in 4 of 14 and 5 of 15 against 0 of 16. Prior advanced therapy failure was more frequent in the 50 mg group (46.2%) than in the 25 mg (39.4%) and placebo (37.5%) groups.
- Phase 2b open-label maintenance study (50 mg, nonresponder imputation): clinical remission at week 96 occurred in 63.8% (76/119) of participants naive to biologics or JAK inhibitors; 38.8% (38/98) of those with prior inadequate response to them were in clinical remission at both weeks 48 and 96.
- Study 108 (25 mg): among participants who completed week 144, clinical remission at week 144 was 90% in the 57 without prior AT-IR and 79% in the 47 with prior AT-IR.

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/); [Danese et al. (2026)](https://www.abivax.com/wp-content/uploads/2026/10/OP260-ABTECT-ATIR-19OCT2026-Danese-UEGW2026.pdf); [Sands et al. (2026a)](https://www.abivax.com/wp-content/uploads/2026/10/OP097-ABTECT-Topline-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-Obe-1.pdf); [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/); [Sands et al. (2026b)](https://www.abivax.com/wp-content/uploads/2026/10/OP107_Obe-3yr-LTE-ATIR-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-BES.pdf)

<a id="topic-1.1.2-5"></a>

##### Summary: phase 2 trials and long-term efficacy

- ABX464-103 (phase 2b, randomized, double-blind, placebo-controlled induction trial; 254 participants randomized, 252 in the full analysis set): for the primary endpoint, the least squares mean change from baseline in modified Mayo score at week 8 was -3.1 with 25 mg, -3.2 with 50 mg, and -2.9 with 100 mg against -1.9 with placebo (p=0.0010, p=0.0003, and p=0.0039 against placebo).
- ABX464-104 (phase 2b open-label maintenance study): 217 participants received obefazimod 50 mg once daily irrespective of their induction treatment or outcome. With nonresponder imputation, clinical remission occurred in 54.8% (119/217) at week 48 and 52.5% (114/217) at week 96, and clinical response in 81.6% (177/217) and 72.8% (158/217); among the 124 participants with clinical response at week 8 of induction, clinical remission at week 96 occurred in 59.7% (74/124). Of the 217 participants, 164 (75.6%) completed week 96. The investigators state that the results “must be interpreted with caution due to the absence of a control group”.
- ABX464-101 (phase 2a, 8 weeks): 32 participants were randomized (23 to obefazimod 50 mg and 9 to placebo), and the registered primary outcome was the number of participants with treatment-emergent adverse events. Clinical remission at week 8 occurred in 35.0% with obefazimod against 11.1% with placebo, a difference the sponsor reported as “p=ns”, and mucosal healing in 50% against 11% (p=0.034).
- ABX464-102 (open-label extension of ABX464-101): 22 participants received obefazimod 50 mg with up to 48 months on treatment; 11 completed the study, and with non-responder imputation, 9 of 22 were in clinical remission at month 48.
- Study 108 (ABX464-108; ongoing single-group, open-label extension; interim analysis presented in a congress poster and a company release): 130 participants who completed ABX464-102 or ABX464-104 with a Mayo endoscopic subscore of 0 or 1 and a rectal bleeding subscore of 0 received obefazimod 25 mg once daily after 2 to 4 years of 50 mg. At study baseline, 89% (116/130) were in clinical remission. With non-responder imputation, clinical remission occurred in 73% (95/130), 69% (90/130), and 68% (88/130) at weeks 48, 96, and 144, and 104 participants (80%) completed week 144.

Source: [Vermeire et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36075249/); [ClinicalTrials.gov NCT03760003 results](https://clinicaltrials.gov/study/NCT03760003?tab=results); [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/); [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm); [ClinicalTrials.gov NCT03093259](https://clinicaltrials.gov/study/NCT03093259); [Abivax ABX464-102 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/Prot_000.pdf); [Abivax press release, phase 2a six-month maintenance data (2019)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-impressive-new-phase-2a-abx464-ulcerative); [ClinicalTrials.gov NCT03368118 results](https://clinicaltrials.gov/study/NCT03368118?tab=results); [ClinicalTrials.gov NCT05177835](https://clinicaltrials.gov/study/NCT05177835); [UEG Week poster, Study 108 three-year analysis (2026)](https://www.abivax.com/wp-content/uploads/2026/10/Final-Poster-3.-Verstockt-OLE-3-yr-Dose-De-Esc.pdf); [Abivax first quarter 2026 results announcement (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-first-quarter-2026-financial-results-and-reports); [Abivax press release, phase 2a Gastroenterology publication (2021)](https://ir.abivax.com/news-releases/news-release-details/abivax-publishes-data-abx464-induction-and-long-term-maintenance); [ClinicalTrials.gov NCT03368118](https://clinicaltrials.gov/study/NCT03368118)

<a id="topic-1.1.2-6"></a>

##### Summary: safety in the induction trials and phase 2 studies

- Pooled ABTECT induction trials (636 participants receiving 50 mg, 319 receiving 25 mg, and 317 receiving placebo): treatment-emergent adverse events (TEAEs) occurred in 60.2%, 48.9%, and 50.8%, serious TEAEs in 3.1%, 2.2%, and 3.2%, and TEAEs leading to study discontinuation in 4.7%, 1.9%, and 4.1%. The most frequent TEAE was headache (23.3%, 15.0%, and 5.7%), with a median duration of 2 to 3 days; nausea occurred in 7.2%, 5.0%, and 1.3%, increased lipase in 4.2%, 2.8%, and 2.2%, and abdominal pain in 3.8%, 0.6%, and 0.6%. Serious, severe, or opportunistic infections occurred in 0.6%, 0.3%, and 0.3%, and the only opportunistic infection was aspergillosis with placebo. One malignancy occurred, a stage I prostate cancer in a participant who had received obefazimod 50 mg for two weeks. In the posted registry results, serious acute pancreatitis occurred in 1 of 318 participants receiving 50 mg in ABTECT-1 and in 1 of 159 receiving 25 mg and 1 of 159 receiving placebo in ABTECT-2.
- ABX464-103 (phase 2b induction): headache was reported in 42% (27/64) with 100 mg, 30% (19/63) with 50 mg, 21% (13/62) with 25 mg, and 8% (5/64) with placebo.
- ABX464-104 (217 participants receiving 50 mg for up to 96 weeks): TEAEs occurred in 68.2% and treatment-emergent serious adverse events in 8.3%. One malignant meningioma and one death (car accident) were reported, both unrelated to treatment.
- Study 108 (130 participants receiving 25 mg through week 144): TEAEs occurred in 73.8%, serious TEAEs in 6.2%, and non-melanoma skin cancer in 1 participant (0.8%); there were no deaths and no opportunistic infections, and the safety table does not include laboratory findings.

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/); [ClinicalTrials.gov NCT05507203 results](https://clinicaltrials.gov/study/NCT05507203?tab=results); [ClinicalTrials.gov NCT05507216 results](https://clinicaltrials.gov/study/NCT05507216?tab=results); [Dulai et al. (2026)](https://www.abivax.com/wp-content/uploads/2026/10/abivax-poster-favorable-safety-acg-2026.pdf); [Seidler et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/Supplement_1/jjaf231.893/8433392); [Vermeire et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36075249/); [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/); [Sands et al. (2026b)](https://www.abivax.com/wp-content/uploads/2026/10/OP107_Obe-3yr-LTE-ATIR-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-BES.pdf)

<a id="topic-1.1.2-7"></a>

##### Summary: safety in ABTECT Maintenance, including malignancies

- Part 1 over 44 weeks (192 participants receiving placebo, 193 receiving 25 mg, and 195 receiving 50 mg): TEAEs occurred in 50.0%, 58.0%, and 71.8%, serious TEAEs in 4.2%, 2.6%, and 5.6%, and TEAEs leading to study drug discontinuation in 6.8%, 2.6%, and 4.6%. There were no deaths. Serious or severe infections and opportunistic infections occurred in 1.0%, 1.0%, and 0.5%, including one lymph node tuberculosis with 25 mg. No acute pancreatitis or cardiac abnormalities suggestive of cardiac fibrosis were reported, and 2 pregnancies (1.1%) occurred with 50 mg.
- Part 1 malignancies: no malignancy other than non-melanoma skin cancer (NMSC) occurred with placebo or 25 mg, and three occurred with 50 mg, each in 1 participant (0.5%). The company release describes them as the “prostate, breast, and colon cancer cases”, which were “considered unrelated to treatment by investigators”, and the UEG Week 2026 presentation reports “One case of colonic dysplasia” in the 50 mg arm. NMSC occurred in 1 participant with placebo, 1 with 25 mg, and 4 with 50 mg. The company states that “Two of the four 50 mg patients were deemed not/unlikely related to drug by investigators”, and that the mean age of the NMSC cases was 62 years against 42 years in the overall trial population.
- Part 2 over 44 weeks (induction non-responders and Part 1 relapsers, 186 receiving 25 mg and 447 receiving 50 mg, without a placebo group): TEAEs occurred in 71.0% and 68.7%, serious TEAEs in 8.6% and 5.1%, and TEAEs leading to study drug discontinuation in 11.3% and 6.0%. One death occurred with 25 mg, from suspected pulmonary embolism, and was assessed by the investigator as unrelated to obefazimod. Acute pancreatitis occurred in 1 participant in each group (0.5% and 0.2%).
- Part 2 malignancies: malignancies excluding NMSC occurred in none with 25 mg and 2 with 50 mg (0.4%), a myeloproliferative neoplasm and a prostate cancer, both in Part 1 placebo relapsers and both determined by the investigator as not related to study drug. NMSC occurred in 2 participants with 25 mg (1.1%) and 2 with 50 mg (0.4%); the investigator determined one NMSC case with 50 mg and one with 25 mg “probably related to study drug”. The company states that the NMSC events “all occurred in patients with established NMSC risk factors including advanced age, thiopurine use, prior skin cancer history and failure of multiple prior advanced therapies”.
- Exposure-adjusted incidence (post hoc company analyses): in the phase 3 maintenance dataset (Part 1 and Part 2), the incidence of malignancies excluding NMSC per 100 patient-years was 0.00 with placebo, 0.00 with 25 mg, 0.91 with 50 mg, and 0.56 with both doses combined, and the incidence of NMSC was 0.68, 1.09, 1.37, and 1.26. The company sets these rates beside expected ulcerative colitis background ranges drawn from published studies (0.30 to 0.70 for malignancies excluding NMSC and 0.70 to 1.40 for NMSC) and states that the rates of the combined active arms are “within the UC background reference range based on published UC studies”. Across the integrated phase 2 and phase 3 ulcerative colitis trials (1,704 patient-years), the rates with both doses combined were 0.35 for malignancies excluding NMSC and 0.59 for NMSC, against 0.00 and 0.46 with placebo.
- Data safety monitoring board reviews in December 2025 and March 2026 found no new safety signals.

Source: [Abivax press release, ABTECT maintenance results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-landmark-phase-3-abtect-maintenance-trial); [Sands et al. (2026a)](https://www.abivax.com/wp-content/uploads/2026/10/OP097-ABTECT-Topline-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-Obe-1.pdf); [Abivax prospectus supplement (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000119312526290817/d111359d424b5.htm); [Abivax press release, ABTECT maintenance Part 2 results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-positive-abtect-maintenance-part-2-results); [Abivax press release, 2026 corporate outlook (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-provides-2026-corporate-outlook); [Abivax full year 2025 results announcement (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-full-year-2025-financial-results-and-provides)

<a id="topic-1.1.2-8"></a>

##### Summary: pharmacology, pharmacokinetics, special populations, and drug interactions

- Mechanism and pharmacodynamics: obefazimod is an oral small molecule that “selectively enhances the expression of a single micro-RNA (miRNA), miR-124”. It binds the cap binding complex, and its N-glucuronide metabolite (ABX464-N-Glu) is pharmacologically active and binds the same complex. In the ABTECT induction trials, obefazimod increased miR-124 expression in blood and in rectal and sigmoidal tissue at Week 8 and reduced serum IL-17A (p<0.0001 against placebo) and IL-6 (p=0.0150 with 25 mg and p=0.0039 with 50 mg), which the abstract authors describe as “nominally statistically significant reductions”.
- Pharmacokinetics: after a single fasting dose, obefazimod reached its maximum concentration about 2 hours after administration and was rapidly metabolized to the N-glucuronide, whose maximum concentration was about 160-fold higher than that of the parent drug and whose half-life was 90 to 110 hours. The parent drug has a half-life of about 1 hour. Obefazimod is metabolized by glucuronidation, and steady state was reached after 4 weeks of repeated dosing. In a food-effect study, Cmax and AUC of obefazimod were “demonstrated to increase with food after a single dose of ABX464 (219% and 188%, respectively)”, and the increase for the metabolite was “much more limited”; the phase 3 protocol states that food increased obefazimod exposure “by at least 3- to 4-fold”. The interaction study protocol identifies CYP1A2 as the major isoform of the oxidative route of metabolism and reports that obefazimod inhibited CYP1A2 in human liver microsomes and induced its expression in human hepatocytes.
- Special populations: a phase 1 study in mild and moderate hepatic impairment enrolled 30 participants, and its results are to be published from 11 March 2027; a phase 1 study in renal impairment is registered in the EU Clinical Trials Information System. The ABTECT induction trials excluded participants with creatinine clearance below 60 mL/min or AST or ALT above 2 times the upper limit of normal. Of the 1,272 participants in the ABTECT induction trials, 89 were 65 years or older, and TEAEs in this group occurred in 65.9% (50 mg), 38.9% (25 mg), and 55.6% (placebo). In ABTECT, women of childbearing potential were to use at least one highly effective method of contraception, and 2 pregnancies were reported with 50 mg in ABTECT Maintenance Part 1. A European paediatric investigation plan includes a study in patients aged 2 years to less than 18 years.
- Drug interactions (phase 1 study ABX464-902 in healthy adults; mean values as posted): with fluvoxamine, a CYP1A2 inhibitor, mean obefazimod Cmax was 33.4 ng/mL against 23.2 ng/mL alone, and mean AUC 73.0 against 55.2 h*ng/mL (25 participants); the plain-language research summary states that obefazimod “may be metabolised in the same pathway as fluvoxamine”. With caffeine, a CYP1A2 substrate, mean caffeine AUC was 7420 h*ng/mL alone, 5460 h*ng/mL with the first obefazimod dose, and 1560 h*ng/mL after 14 days of obefazimod, and mean caffeine Cmax was 931, 930, and 564 ng/mL (22 participants); the plain-language summary states that caffeine and fluvoxamine levels “remained similar in both the presence and absence of ABX464”. Results of interaction studies with rosuvastatin and with a combined oral contraceptive (ethinyl estradiol and drospirenone) are to be published from 20 August 2027 and 28 February 2027.

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/); [Vautrin et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6349857/); [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf); [Siegmund et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/Supplement_1/jjaf231.1049/8433989); [Scherrer et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/27999038/); [Steens et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5487684/); [Scherrer et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5192114/); [Abivax ABX464-902 protocol and statistical analysis plan (2021)](https://cdn.clinicaltrials.gov/large-docs/14/NCT05121714/Prot_SAP_000.pdf); [CTIS.eu 2023-505299-31-00](https://ctis.eu/trial/2023-505299-31-00); [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm); [EU Clinical Trials Information System 2024-514561-20-00](https://euclinicaltrials.eu/ctis-public/view/2024-514561-20-00); [Yarur et al. (2026)](https://www.abivax.com/wp-content/uploads/2026/04/abivax-poster-elderly-yarur-ddw-2026.pdf); [Sands et al. (2026a)](https://www.abivax.com/wp-content/uploads/2026/10/OP097-ABTECT-Topline-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-Obe-1.pdf); [EMA paediatric investigation plan decision, March 2025 (2025)](https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000189672-ema-decision-20-march-2025-acceptance-modification-agreed-paediatric-investigation-plan-obefazimod_en.pdf); [ClinicalTrials.gov NCT05121714 results](https://clinicaltrials.gov/study/NCT05121714?tab=results); [Health Research Authority research summary, ABX464 drug-drug interaction study](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/a-2-part-drug-drug-interaction-study-of-abx464-in-healthy-volunteers); [CTIS.eu 2023-509226-21-00](https://ctis.eu/trial/2023-509226-21-00); [CTIS.eu 2023-505297-15-00](https://ctis.eu/trial/2023-505297-15-00)

<a id="heading-1.1.3"></a>

#### 1.1.3 Budget Impact of Obefazimod

<a id="topic-1.1.3-1"></a>

##### Summary

Obefazimod is investigational. Abivax states that it “has not yet been approved for commercial use in any jurisdiction”, and that the company “remains on track to submit its NDA to the U.S. Food and Drug Administration in the fourth quarter of 2026.” No FDA application has been submitted, and no peer-reviewed full publication of the ABTECT trials was identified as of November 2026. No budget impact model, cost-effectiveness analysis, or health technology assessment of obefazimod was identified, and obefazimod has no wholesale acquisition cost or average sales price. The one obefazimod price figure is an analyst assumption: LifeSci Capital, in June 2026, assumed a “net annual price at launch of US$78,000 in the U.S.”, increased from US$66,000 “based on recent management commentary”, with a 90% probability of success and market entry in 2027.

Source: [Abivax obefazimod web page](https://www.abivax.com/our-science/obefazimod/); [Abivax press release, ABTECT maintenance Part 2 results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-positive-abtect-maintenance-part-2-results); [Streetwise Reports (2026)](https://www.streetwisereports.com/article/2026/07/01/clinical-stage-biotech-discloses-colitis-retreatment-results-gets-mixed-ratings.html)

<a id="topic-1.1.3-2"></a>

##### Summary: eligible population

In the United States, the age-, sex- and insurance-standardized prevalence of ulcerative colitis was 378 per 100,000 (95% CI 375 to 382), which the authors extrapolated to an estimated 1.253 million Americans using the 2020 census population. Across the study's alternative estimates, prevalence ranged from 312 per 100,000 to 438 per 100,000. ICER's 2026 Medicare assessment reports approximately 160,000 people with ulcerative colitis (0.64%) among 25 million Medicare fee-for-service beneficiaries.

ICER's 2020 review estimated its eligible population from a U.S. prevalence of approximately 900,000 patients and the Crohn's and Colitis Foundation report that approximately 22% of patients “have moderate-to-severe disease activity in a given year”, which ICER equated to approximately 198,000 patients; it assumed a fixed ratio of 55% biologic-naive and 45% biologic-experienced patients. In a Copenhagen cohort diagnosed in 2003 to 2004, early disease activity was moderate-to-severe in 24%. No more recent peer-reviewed estimate of the moderate-to-severe share was identified. Among 3,893 patients with newly diagnosed ulcerative colitis, cumulative use of advanced therapy was 17% at 1 year and 29% at 5 years, and 27% and 38% in the cohort diagnosed in 2019 to 2023.

Abivax estimates that U.S. advanced therapy use increased by approximately 96%, from approximately 138,000 patients in 2020 to approximately 271,000 in 2025, and that approximately 300,000 moderate-to-severe patients, out of an estimated 500,000, are on conventional therapy or steroids only. In company-reported research, physicians indicated they “would likely initiate treatment with obefazimod for this population”. Abivax reports U.S. ulcerative colitis sales of approximately $6.0 billion in 2025, expected to reach $14.9 billion by 2032. These figures are company estimates.

Source: [Lewis et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10592313/); [ICER special assessment of Entyvio to inform CMS negotiation (2026)](https://icer.org/wp-content/uploads/2026/03/Entyvio_Final-Evidence-Report_For-Publication_030326.pdf); [ICER Targeted Immune Modulators for Ulcerative Colitis final evidence report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_UC_Final_Evidence_Report_101620.pdf); [Fumery et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6658168/); [Ahuja et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13456955/); [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm); [Abivax press release, 2026 corporate outlook (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-provides-2026-corporate-outlook)

<a id="topic-1.1.3-3"></a>

##### Summary: comparator costs and published budget impact methods

ICER's 2026 Medicare model, based on January 21, 2026 price estimates, gives annual net costs of maintenance of $39,423 for intravenous vedolizumab, $67,145 for subcutaneous vedolizumab, $5,430 for an intravenous infliximab biosimilar in ulcerative colitis, $78,435 for subcutaneous infliximab, and $27,221 for a subcutaneous ustekinumab biosimilar (90 mg). The Medicare negotiated price of Stelara (ustekinumab) for calendar year 2026 is $4,695.00 per 30-day supply, a 66% discount from its 2023 list price of $13,836.00. Vedolizumab (Entyvio) and tofacitinib (Xeljanz, Xeljanz XR) were selected for Medicare price negotiation, with any negotiated prices “effective beginning in 2028.” Wholesale acquisition costs of the oral advanced therapies reported to California are $6,407.16 for 60 tablets of tofacitinib 10 mg (January 2026), $6,752.77 for 30 tablets of upadacitinib 15 mg or 30 mg (January 2025), $9,289.90 for 30 capsules of ozanimod 0.92 mg (January 2025), and $6,164.38 for 30 tablets of etrasimod 2 mg at introduction (October 2023). These figures differ in date and in price basis (net, negotiated, or list).

ICER's 2020 potential budget impact analysis of ustekinumab used undiscounted costs over a five-year time horizon and a threshold of approximately $819 million per year for new drugs. Approximately 21% of eligible patients could be treated in a given year at the wholesale acquisition cost of ustekinumab, and approximately 51% at its estimated net price, without crossing that threshold. The annualized per-patient net budget impact over five years was $36,100 at list price and $15,600 at net price, against a market basket cost of $37,500. The 2020 model assumed $33,871 per admission for colectomy and $10,238 per serious infection event, and annual health-state costs of $8,048 for hospitalization, $581 for emergency department care, and $10,114 for outpatient or other care in active ulcerative colitis, against $969, $223, and $2,722 in clinical remission.

Source: [ICER special assessment of Entyvio to inform CMS negotiation (2026)](https://icer.org/wp-content/uploads/2026/03/Entyvio_Final-Evidence-Report_For-Publication_030326.pdf); [CMS fact sheet, negotiated prices for initial price applicability year 2026 (2024)](https://cms.gov/files/document/fact-sheet-negotiated-prices-initial-price-applicability-year-2026.pdf); [CMS fact sheet, third cycle of negotiation (2026)](https://www.cms.gov/files/document/fact-sheet-medicare-drug-price-negotiation-third-cycle.pdf); [California Department of Health Care Access and Information Prescription Drug Wholesale Acquisition Cost Increases (2026)](https://data.chhs.ca.gov/api/3/action/datastore_search_sql?sql=SELECT%20%22manufacturer_name%22%2C%22ndc%22%2C%22drug_prod_desc%22%2C%22wac_effective_date%22%2C%22wac_increase_amount%22%2C%22wac_after_increase%22%20FROM%20%22dda8a083-bc81-4f6d-b02f-935a2df70328%22%20WHERE%20%22drug_prod_desc%22%20LIKE%20%27SKYRIZI%25%27%20OR%20%22drug_prod_desc%22%20LIKE%20%27Xeljanz%25%27%20OR%20%22drug_prod_desc%22%20LIKE%20%27Entyvio%25%27); [California Department of Health Care Access and Information Prescription Drug Wholesale Acquisition Cost Increases (2025)](https://data.chhs.ca.gov/api/3/action/datastore_search_sql?sql=SELECT%20%22Manufacturer%20Name%22%2C%22NDC%20Number%22%2C%22Drug%20Product%20Description%22%2C%22WAC%20Effective%20Date%22%2C%22WAC%20Increase%20Amount%22%2C%22WAC%20After%20Increase%22%20FROM%20%2246b78eef-5952-4fff-84c7-1fa758990ce8%22%20WHERE%20%22Drug%20Product%20Description%22%20LIKE%20%27RINVOQ%25%27%20OR%20%22Drug%20Product%20Description%22%20LIKE%20%27ZEPOSIA%25%27); [California Department of Health Care Access and Information Prescription Drugs Introduced to Market (2023)](https://data.chhs.ca.gov/api/3/action/datastore_search_sql?sql=SELECT%20%22Manufacturer%20Name%22%2C%22NDC%20Number%22%2C%22Drug%20Product%20Description%22%2C%22Date%20Introduced%20to%20Market%22%2C%22WAC%20at%20Introduction%22%20FROM%20%22f0899438-0fb5-42d5-87f5-621e2f0b1b51%22%20WHERE%20%22Drug%20Product%20Description%22%20LIKE%20%27VELSIPITY%25%27%20OR%20%22Drug%20Product%20Description%22%20LIKE%20%27OMVOH%25%27); [ICER Targeted Immune Modulators for Ulcerative Colitis final evidence report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_UC_Final_Evidence_Report_101620.pdf)

<a id="heading-1.1.4"></a>

#### 1.1.4 Conclusions

<a id="topic-1.1.4-1"></a>

##### Summary

Obefazimod is an investigational “oral small molecule” for moderately to severely active ulcerative colitis. Abivax states that it “has not yet been approved for commercial use in any jurisdiction”, and no new drug application (NDA) has been submitted to the FDA. In the two 8-week, placebo-controlled induction trials, clinical remission at Week 8 (primary endpoint) with obefazimod 50 mg occurred in 21.7% against 2.5% with placebo in ABTECT-1 (difference 19.3%, p<0.0001) and in 19.8% against 6.3% in ABTECT-2 (difference 13.4%, p=0.0001); with 25 mg it occurred in 23.8% in ABTECT-1 (difference 21.4%, p<0.0001) and in 11.3% in ABTECT-2 (difference 5.1%, p=0.1034). In a pooled analysis with nominal p-values, clinical remission with 50 mg occurred in 13.3% against 3.4% with placebo among participants with a prior inadequate response to advanced therapy and in 27.7% against 5.3% among those without. In ABTECT Maintenance, among 580 obefazimod induction responders re-randomized for 44 weeks, clinical remission at Week 44 (primary endpoint) occurred in 50.8% with 25 mg and 51.3% with 50 mg against 10.4% with placebo (p<0.0001). Headache was the most frequent treatment-emergent adverse event in the induction trials (20.8% to 25.8% with 50 mg, 14.5% to 15.6% with 25 mg, and 5.7% with placebo).

No peer-reviewed full publication of any ABTECT trial exists as of November 2026; the results come from congress abstracts and presentations, company press releases and filings, and the posted registry results of the induction trials, and the ClinicalTrials.gov record of the maintenance trial shows “No Results Posted”. Each phase 3 trial compared obefazimod with placebo, and no trial comparing obefazimod with another advanced therapy was identified. In Part 1 of ABTECT Maintenance, malignancies other than non-melanoma skin cancer (NMSC) occurred only with 50 mg, one prostate cancer, one breast cancer, and one colonic dysplasia, which the company release calls the “prostate, breast, and colon cancer cases”; NMSC occurred in 1 participant with placebo, 1 with 25 mg, and “four 50 mg patients”. Part 2, which has no placebo group, reported “two non-NMSC malignancies” with 50 mg and four NMSC events, and the investigator determined one basal cell carcinoma (50 mg) and one squamous cell carcinoma (25 mg) “probably related to study drug”. In the company's “integrated post-hoc analyses”, the exposure-adjusted incidence in the phase 3 maintenance dataset with 50 mg was 0.91 per 100 patient-years for malignancies excluding NMSC and 1.37 for NMSC, which the company sets beside expected ulcerative colitis background ranges of 0.30 to 0.70 and 0.70 to 1.40, and the company states that the rates of the combined active arms are “within the UC background reference range based on published UC studies”. Results of phase 1 studies are deferred in the EU register, to be published from 28 February 2027 (combined oral contraceptive interaction), 11 March 2027 (hepatic impairment), 20 August 2027 (rosuvastatin interaction), and 14 April 2028 (renal impairment).

Abivax states that it “remains on track to submit its first NDA for obefazimod by the end of 2026”. The outcome of FDA review, the approved indication, dose, and labeling, and the price are unknown. Obefazimod has no wholesale acquisition cost or average sales price; the one price figure identified is an analyst assumption by LifeSci Capital of a “net annual price at launch of US$78,000 in the U.S.” No budget impact model, cost-effectiveness analysis, or health technology assessment of obefazimod was identified.

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/); [Abivax obefazimod web page](https://www.abivax.com/our-science/obefazimod/); [Abivax press release, ABTECT induction results (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-phase-3-results-both-abtect-8-week); [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/); [Abivax press release, ABTECT maintenance results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-landmark-phase-3-abtect-maintenance-trial); [ClinicalTrials.gov NCT05535946](https://clinicaltrials.gov/study/NCT05535946); [Sands et al. (2026a)](https://www.abivax.com/wp-content/uploads/2026/10/OP097-ABTECT-Topline-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-Obe-1.pdf); [Abivax press release, ABTECT maintenance Part 2 results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-positive-abtect-maintenance-part-2-results); [Abivax prospectus supplement (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000119312526290817/d111359d424b5.htm); [CTIS.eu 2023-505297-15-00](https://ctis.eu/trial/2023-505297-15-00); [CTIS.eu 2023-505299-31-00](https://ctis.eu/trial/2023-505299-31-00); [CTIS.eu 2023-509226-21-00](https://ctis.eu/trial/2023-509226-21-00); [CTIS.eu 2024-514561-20-00](https://ctis.eu/trial/2024-514561-20-00); [EU Clinical Trials Information System 2024-514561-20-00](https://euclinicaltrials.eu/ctis-public/view/2024-514561-20-00); [Abivax press release, pre-NDA interaction with the FDA (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-pre-nda-interaction-fda-obefazimod); [Streetwise Reports (2026)](https://www.streetwisereports.com/article/2026/07/01/clinical-stage-biotech-discloses-colitis-retreatment-results-gets-mixed-ratings.html)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
